Dimiter S Dimitrov

List of Publications by Year
in descending order

89 papers	6,951 citations	66343 42 h-index	62596 80 g-index
101 all docs	101 docs citations	101 times ranked	9275 citing authors

#	Article	IF	Citations
1	A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo. Cancer Letters, 2022, 525, 97-107.	7.2	12
2	Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells. Translational Oncology, 2022, 15, 101265.	3.7	8
3	Design of a Novel Fabâ€Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. Small Methods, 2022, 6, 2100966.	8.6	1
4	Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nature Communications, 2022, 13, 742.	12.8	71
5	An insulin growth factor-I/II-neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth. Journal of Cancer, 2022, 13, 1830-1836.	2.5	3
6	Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22. Frontiers in Immunology, 2022, 13, 869825.	4.8	8
7	Functional reconstitution of the MERS CoV receptor binding motif. Molecular Immunology, 2022, 145, 3-16.	2.2	2
8	Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs. Cancer Research, 2021, 81, 671-684.	0.9	39
9	Trispecific CD19-CD20-CD22â€“targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Science Translational Medicine, 2021, 13, .	12.4	77
10	Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. PLoS Biology, 2021, 19, e3001237.	5.6	171
11	Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma. Cancer Discovery, 2021, 11, 2884-2903.	9.4	51
12	The reduced form of the antibody CH2 domain. Protein Science, 2021, 30, 1895-1903.	7.6	1
13	Abstract 1545: Development of FGFR4-targeted chimeric antigen receptors (CARs) for the treatment of rhabdomyosarcoma. , 2021, , .		0
14	A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell Reports Medicine, 2021, 2, 100344.	6.5	14
15	Abstract 1546: Defining the immune microenvironment in Ewing's sarcoma to potentiate IL1RAP-targeted CAR-T immunotherapy. , 2021, , .		0
16	Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22. Journal of Biological Chemistry, 2021, 297, 100966.	3.4	7
17	Antibodyâ€“Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. Molecular Cancer Therapeutics, 2021, 20, 2228-2239.	4.1	8
18	Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody. Translational Oncology, 2021, 14, 101232.	3.7	6

#	Article	IF	Citations
19	Developability Assessment of an Isolated C_H2 Immunoglobulin Domain. Analytical Chemistry, 2021, 93, 1342-1351.	6.5	6
20	Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related Diseases. International Journal of Molecular Sciences, 2021, 22, 11136.	4.1	7
21	Immune Modulating Antibodyâ€"Drug Conjugate (IM-ADC) for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 15716-15726.	6.4	35
22	Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. Cell Reports, 2021, 37, 110156.	6.4	67
23	An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding. MAbs, 2020, 12, 1689027.	5.2	7
24	High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. Cell, 2020, 183, 429-441.e16.	28.9	100
25	Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Vaccine, 2020, 38, 7205-7212.	3.8	31
26	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29832-29838.	7.1	81
27	Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Science Translational Medicine, 2020, 12, .	12.4	34
28	Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. Lancet Infectious Diseases, The, 2020, 20, 445-454.	9.1	60
29	Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Science Translational Medicine, 2019, 11, .	12.4	104
30	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. Journal of Virology, 2019, 93, .	3.4	8
31	A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III. PLoS Pathogens, 2019, 15, e1007836.	4.7	32
32	Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV. Antibodies, 2019, 8, 53.	2.5	8
33	Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro. Antibodies, 2019, 8, 25.	2.5	10
34	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. Aids, 2018, 32, 1749-1761.	2.2	11
35	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine, 2018, 24, 20-28.	30.7	1,030
36	Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation. Biochemical and Biophysical Research Communications, 2017, 485, 446-453.	2.1	19

#	Article	IF	Citations
37	HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. Emerging Microbes and Infections, 2017, 6, 1-7.	6.5	21
38	Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Research, 2017, 143, 30-37.	4.1	56
39	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host and Microbe, 2017, 22, 471-483.e5.	11.0	48
40	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell, 2017, 32, 295-309.e12.	16.8	148
41	PotentIn VivoNK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. Journal of Virology, 2017, 91, .	3.4	31
42	Human monoclonal antibodies as candidate therapeutics against emerging viruses. Frontiers of Medicine, 2017, 11, 462-470.	3.4	38
43	Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Scientific Reports, 2016, 6, 31629.	3.3	50
44	Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)â€“Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection. Journal of Infectious Diseases, 2016, 213, 1557-1561.	4.0	84
45	A dualâ€specific antiâ€<scp>IGFâ€1/IGFâ€2</scp> human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma. International Journal of Cancer, 2015, 137, 2243-2252.	5.1	19
46	Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies. PLoS ONE, 2015, 10, e0126428.	2.5	9
47	Germlining of the HIV-1 broadly neutralizing antibody domain m36. Antiviral Research, 2015, 116, 62-66.	4.1	2
48	Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials, 2015, 41, 141-150.	11.4	58
49	Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nature Communications, 2015, 6, 6536.	12.8	115
50	Targeting of folate receptor Î² on acute myeloid leukemia blasts with chimeric antigen receptorâ€“expressing T cells. Blood, 2015, 125, 3466-3476.	1.4	148
51	Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nature Communications, 2015, 6, 8223.	12.8	106
52	Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. MAbs, 2015, 7, 922-930.	5.2	25
53	No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5115-E5115.	7.1	1
54	Assessment of folate receptor-Î² expression in human neoplastic tissues. Oncotarget, 2015, 6, 14700-14709.	1.8	64

#	Article	IF	Citations
55	Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases. MAbs, 2014, 6, 1201-1210.	5.2	24
56	Therapeutic Treatment of Nipah Virus Infection in Nonhuman Primates with a Neutralizing Human Monoclonal Antibody. Science Translational Medicine, 2014, 6, 242ra82.	12.4	117
57	The Antibody Germline/Maturation Hypothesis, Elicitation of Broadly Neutralizing Antibodies Against HIV-1 and Cord Blood IgM Repertoires. Frontiers in Immunology, 2014, 5, 398.	4.8	15
58	Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies. Journal of Virology, 2014, 88, 7796-7805.	3.4	212
59	Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains. Journal of Virology, 2014, 88, 1125-1139.	3.4	51
60	Engineered Fc based antibody domains and fragments as novel scaffolds. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1977-1982.	2.3	33
61	Discovery of Novel Candidate Therapeutics and Diagnostics Based on Engineered Human Antibody Domains. Current Drug Discovery Technologies, 2014, 11, 28-40.	1.2	20
62	Anti-CD22â€“chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, 2013, 121, 1165-1174.	1.4	478
63	Engineered Soluble Monomeric IgG1 CH3 Domain. Journal of Biological Chemistry, 2013, 288, 25154-25164.	3.4	46
64	Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity. PLoS ONE, 2013, 8, e66638.	2.5	8
65	Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. MAbs, 2012, 4, 466-474.	5.2	23
66	Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies. Biochemical and Biophysical Research Communications, 2012, 425, 931-937.	2.1	6
67	A Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus Challenge. Science Translational Medicine, 2011, 3, 105ra103.	12.4	135
68	Shortened Engineered Human Antibody CH2 Domains. Journal of Biological Chemistry, 2011, 286, 27288-27293.	3.4	51
69	Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Research, 2010, 88, 107-115.	4.1	38
70	A large human domain antibody library combining heavy and light chain CDR3 diversity. Molecular Immunology, 2010, 47, 912-921.	2.2	35
71	Therapeutic antibodies, vaccines and antibodyomes. MAbs, 2010, 2, 347-356.	5.2	129
72	Engineered Human Antibody Constant Domains with Increased Stability. Journal of Biological Chemistry, 2009, 284, 14203-14210.	3.4	89

#	Article	IF	Citations
73	Engineered CH2 domains (nanoantibodies). MAbs, 2009, 1, 26-28.	5.2	55
74	Identification and characterization of fully human anti-CD22 monoclonal antibodies. MAbs, 2009, 1, 297-303.	5.2	34
75	A Neutralizing Human Monoclonal Antibody Protects against Lethal Disease in a New Ferret Model of Acute Nipah Virus Infection. PLoS Pathogens, 2009, 5, e1000642.	4.7	251
76	Therapeutic Antibodies: Current State and Future Trends â€“ Is a Paradigm Change Coming Soon?. Methods in Molecular Biology, 2009, 525, 1-27.	0.9	113
77	A large library based on a novel (CH2) scaffold: Identification of HIV-1 inhibitors. Biochemical and Biophysical Research Communications, 2009, 387, 387-392.	2.1	64
78	Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochemical and Biophysical Research Communications, 2009, 390, 404-409.	2.1	239
79	Construction of a Human Antibody Domain (VH) Library. Methods in Molecular Biology, 2009, 525, 81-99.	0.9	26
80	Construction of a Large NaÃ¯ve Human Phage-Displayed Fab Library Through One-Step Cloning. Methods in Molecular Biology, 2009, 525, 129-142.	0.9	49
81	Sequential Antigen Panning for Selection of Broadly Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies. Methods in Molecular Biology, 2009, 562, 143-154.	0.9	4
82	Structure of an isolated unglycosylated antibody C_H2 domain. Acta Crystallographica Section D: Biological Crystallography, 2008, 64, 1062-1067.	2.5	29
83	Construction of a Large Phage-Displayed Human Antibody Domain Library with a Scaffold Based On a Newly Identified Highly Soluble, Stable Heavy Chain Variable Domain. Journal of Molecular Biology, 2008, 382, 779-789.	4.2	72
84	Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17121-17126.	7.1	100
85	Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody. Journal of Infectious Diseases, 2008, 197, 846-853.	4.0	144
86	Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12123-12128.	7.1	276
87	Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody*. Journal of Biological Chemistry, 2006, 281, 15829-15836.	3.4	238
88	Potent Neutralization of Hendra and Nipah Viruses by Human Monoclonal Antibodies. Journal of Virology, 2006, 80, 891-899.	3.4	155
89	The SARS-CoV S glycoprotein: expression and functional characterization. Biochemical and Biophysical Research Communications, 2003, 312, 1159-1164.	2.1	329